Estrogenic hormones, believed to exert most of their effects via the direct interaction of their receptors with chromatin, are found to increase cAMP in target breast cancer and uterine cells in culture and in the intact uterus in vivo. Increases in intracellular cAMP are evoked by very low concentrations of estradiol (half maximal at 10 pM) and by other physiologically active estrogens and antiestrogens, but not by an inactive estrogen stereoisomer. These increases in cAMP result from enhanced membrane adenylate cyclase activity by a mechanism that does not involve genomic actions of the hormones (are not blocked by inhibitors of RNA and protein synthesis). The estrogen-stimulated levels of cAMP are sufficient to activate transcription from cAMP response element-containing genes and reporter plasmid constructs. Our findings document a nongenomic action ofestrogenic hormones that involves the activation of an important second-messenger signaling system and suggest that estrogen regulation of cAMP may provide an additional mechanism by which this steroid hormone can alter the expression of genes.
Increases in intracellular cAMP are evoked by very low concentrations of estradiol (half maximal at 10 pM) and by other physiologically active estrogens and antiestrogens, but not by an inactive estrogen stereoisomer. These increases in cAMP result from enhanced membrane adenylate cyclase activity by a mechanism that does not involve genomic actions of the hormones (are not blocked by inhibitors of RNA and protein synthesis). The estrogen-stimulated levels of cAMP are sufficient to activate transcription from cAMP response element-containing genes and reporter plasmid constructs. Our findings document a nongenomic action ofestrogenic hormones that involves the activation of an important second-messenger signaling system and suggest that estrogen regulation of cAMP may provide an additional mechanism by which this steroid hormone can alter the expression of genes.
For many years, steroid hormones and peptide hormones have been considered to act via distinctly different mechanisms, the former via intracellular receptors acting through the genome (1, 2) and the latter via membrane-localized receptors that initially affect extranuclear activities, including the generation of second messengers such as cAMP. However, there has been increasing evidence for interactions between cAMP and estrogen in enhancing the growth of the mammary gland and breast cancer cells (3, 4) and for cAMP induction of estrogen-like uterine growth (5) . As early as 1967, Szego and Davis (6) demonstrated a very rapid, acute elevation of uterine cAMP by estrogen treatment of rats in vivo that was confirmed in other reports (7, 8) , but several subsequent studies either failed to confirm this observation or reported only minimal effects that were considered to represent indirect effects of estrogen on cAMP mediated by estrogen-induced release of uterine epinephrine (9) (10) (11) (12) . Recently, cAMP and other protein kinase activators have been documented to synergize with steroid hormone-occupied receptors, leading to enhanced steroid receptor-mediated transcription (13) (14) (15) (16) (17) (18) , possibly by a mechanism involving phosphorylation of the receptor or associated transcription factors (14, (19) (20) (21) .
In this paper, we show that estrogen activates adenylate cyclase, markedly increasing the concentration of cAMP in estrogen-responsive breast cancer and uterine cells in culture and in the intact uterus of rats treated with estrogen in vivo, in a manner that does not require new RNA or protein synthesis. The intracellular concentrations of cAMP achieved by low, physiological levels of estrogen are substantial and sufficient to stimulate cAMP response element (CRE)-mediated gene transcription. Therefore, this nongenomic action of the steroid hormone estrogen involves the production of an important second messenger and the resultant activation of second messenger-stimulated genes. These findings document a two-way directionality in the cross talk between steroid hormone-and cAMP-signaling pathways.
MATERIALS AND METHODS
Plasmid DNA. The SRIF-CAT plasmid (22) , containing the CRE region of the somatostatin [somatotropin releaseinhibiting factor (SRIF)] gene promoter linked to the gene encoding chloramphenicol acetyltransferase (CAT), was kindly provided by Marc Montminy (Salk Institute, La Jolla, CA). PRd-CAT, containing the distal promoter of the rat progesterone receptor (PR) gene linked to the CAT gene, has been described (23). pS2-CAT was constructed by replacing the thymidine kinase (tk) promoter of pTZ-tk-CAT (23) , released by digestion with BamHI and Bgl II, with the promoter region of the gene encoding protein pS2 (-90 to +10; ref. 24) , which was released from a genomic clone provided by Pierre Chambon (Institut National de la Sante et de la Recherche Medicale, Strasbourg, France) by BamHI digestion. The PRd and pS2 promoter regions do not contain any estrogen-response elements (EREs) or CREs and are unresponsive to 173-estradiol (E2) and cAMP (refs. 23 and 24 and our unpublished observations). CRE-pS2-CAT and CRE-PRd-CAT were constructed by annealing the oligonucleotide 5'-TGGCTGACGTCAGAGA-3' with its complement and cloning the resulting double-stranded oligomer, which contains the CRE of the rat somatostatin gene and its immediate flanking sequences (22) into Sma I-digested pS2-CAT and PRd-CAT, respectively.
Cell Culture, Transfections, and CAT Assays. Primary cultures of uterine cells from 18-day-old Sprague-Dawley rats (Holtzmann, Madison, WI) were prepared and maintained as described (14) . MCF-7 human breast cancer cells were maintained as described (23) and were switched to culture medium lacking phenol red 2 days prior to plating for experiments. For cAMP studies, uterine and MCF-7 cells were plated at a density of 1.5-2 x 106 cells per 160-mm dish.
For transfection experiments, both cell types were plated at 4_5 x 106 cells per 100-mm dish, and the medium was changed 48 hr later. Cells were transfected 24 hr later as described (14, 23) Proc. Natl. Acad. Sci. USA 91 (1994) were harvested 24 hr later. CAT assays, normalized for the f3-galactosidase activity of each extract, were performed as described (14) . (25) . In brief, homogenates in 75 mM Tris'HCl, pH 7.4/2 mM EDTA/8 mM MgCl2 were subjected to two centrifugations (1000 x g for 5 min at 4°C and 40,000 x g for 20 min at 4°C). Membrane protein (20 pg) was used from each sample. Reaction conditions were as described (25) 
RESULTS
We first examined the effects of estrogen on cAMP in two estrogen-responsive cell types-namely, MCF-7 human breast cancer cells, which contain high levels of endogenous estrogen receptor (ER) and primary cultures of rat uterine cells, which contain lower levels of ER (Fig. 1) . In both cell systems in culture, we observed that the estrogen E2 increased cAMP levels dramatically, as did the antiestrogens trans-hydroxytamoxifen (TOT) and ICI 164,384, although the response to antiestrogen was somewhat lower. Maximal, ca. 10-fold, increases in intracellular cAMP, monitored by RIA, were observed at 0.5 or 1 hr after exposure to E2 in MCF-7 and uterine cells, respectively; these represented changes that were one-third to one-half ofthose achieved by exposure to cholera toxin (CT), a powerful stimulator of adenylate cyclase activity. Intracellular cAMP levels returned to the control level by 6 (28) . Dose-response studies reveal that low, physiological concentrations of E2 were able to stimulate cAMP accumulation (Fig. 2) . Half-maximal stimulation was achieved with ca. 10 pM E2 and full stimulation with 1 nM E2. Slightly higher concentrations ofICI 164,384 and TOT were needed for equal stimulation ofintracellular cAMP, consistent with their lower availability in serum-containing medium and their restricted entry into cells. A nearly identical dose-response relationship was observed for cAMP stimulation by these ligands in rat uterine cells (data not shown).
The hormone specificity of the cAMP stimulation was examined in MCF-7 and uterine cells ( Table 1 ). The potent estrogens E2 and diethylstilbestrol (DES) evoked large fold increases in cAMP, although DES (at 1 nM) was less effective than E2, while the weaker estrogen 2-hydroxyestrone (2-OHestrone) effected a substantial but smaller increase in cAMP; the E2 stereoisomer 17a-estradiol, known to be biologically ineffective as an estrogen, failed to alter intracellular cAMP. The glucocorticoid dexamethasone and the androgen testosterone failed to increase cAMP. As seen in Table 1 , nearly identical results were observed in both cell types.
The ability of estrogen to increase cAMP was associated with increased adenylate cyclase activity, with no significant change in PDE activity (Fig. 3) (Fig. 1) would also be consistent with the apparent absence of a requirement for RNA or protein synthesis.
Since estrogens and antiestrogens increased intracellular cAMP, we asked whether the changes in cAMP were significant enough to affect transcriptional activation of cAMPregulated genes. To examine this, cells were transfected with a cAMP-responsive gene construct (SRIF-CAT) containing the CRE region of the somatostatin gene promoter (-71 to +55) linked to a CAT reporter gene (22) . Cells were treated as shown in Fig. 4 , and CAT activity was measured at 24 hr. E2 exposure evoked a 5-fold (uterine cells) or 13-fold (MCF-7 cells) increase in CRE-mediated CAT activity, nearly equal to that evoked by exposure of cells to 0.1 mM 8-bromocAMP. As expected, CT evoked an even larger response based on its greater and more prolonged elevation of cAMP. TOT and ICI 164,384 also stimulated SRIF-CAT activity, although less dramatically than E2, consistent with their lesser stimulation of intracellular cAMP. The effects of E2 and CT or cAMP were not additive, consistent with their action via the same pathway. The effects of E2 plus antiestrogen were also not additive. Insulin-like growth factor 1, which failed to increase intracellular cAMP (data not shown), also failed to increase SRIF-CAT transcription.
The SRIF-CAT cAMP-responsive reporter gene construct contains the somatostatin promoter and flanking region (-71 to +55) and thus might potentially contain elements other than CREs that might contribute to the response to the hormonal agents. Therefore, we prepared two more simple consensus CRE-containing CAT reporter plasmids; the first contained one CRE upstream of the pS2 promoter (-90 to +10) and CAT gene (CRE-pS2-CAT), and the second contained one CRE upstream of the rat PR gene distal promoter and CAT gene (CRE-PRd-CAT). Transactivation of these reporter genes was stimulated by estrogen and cAMP (Fig.  5) , as seen for the SRIF-CAT plasmid, confirming that transactivation of the SRIF-CAT plasmid was indeed mediated via the CRE and, therefore, was due to intracellular cAMP generated by the hormone. The lack of response to E2 or cAMP in control plasmids (pS2-CAT or PRd-CAT) containing the pS2 or rat PR promoters and CAT reporter gene but lacking the CRE further confirms the requirement for the CRE in the transactivation.
The possibility of any binding of ER to consensus CRE monomers and dimers was analyzed by standard and competitive gel mobility-shift assays using human ER overexpressed in COS-1 cells (29) . In the standard gel mobility-shift assay, direct binding of ER to a radiolabeled CRE dimer could not be detected, whereas binding of bacterially exCell Biology: Aronica et pressed CREB protein (CRE-binding protein; provided by Richard Goodman, Vollum Institute, Portland, OR) was observed (not shown). In the competitive assay, where the binding of ER to radiolabeled consensus EREs was done in the presence of increasing amounts (up to 400-fold excess) of unlabeled CRE monomer or CRE dimer, no competition at all was observed, suggesting no interaction of ER with the CREs (not shown); however, with unlabeled ERE, a 5-fold molar excess gave nearly complete competition. DISCUSSION Three pieces of evidence indicate that the cAMP stimulation by estrogen and antiestrogens is mediated by a high-affinity hormone binder, possibly the ER: first, the steroid specificity and relative effectiveness ofdifferent estrogens in stimulation of cAMP (Table 1) ; second, the low concentrations of E2 needed for the cAMP stimulation response (Fig. 2) (30, 31) . Therefore, the cAMP increase evoked by estrogen is unusual in that prior RNA and protein synthesis are not required. It is also of interest that both estrogens and antiestrogens have stimulatory effects on cellular cAMP levels and enhance CRE-mediated gene transcription. Both categories of ligands also increase ER phosphorylation, and for both end-points, E2 is somewhat more stimulatory than the antiestrogens (14, 19, 20) . By contrast, antiestrogens fail to stimulate, or stimulate only weakly, the transcription of genes containing EREs, which are strongly activated by estrogen (refs. 13, 14 , and 23 and references therein).
The clear change in adenylate cyclase activity in response to estrogen suggests a possible membrane action of this hormone, an aspect that will require further study. There is now evidence for ER-like binding sites for estrogens (32) and glucocorticoid receptor-like binding sites for glucocorticoids in the cell membrane (33) . Earlier work (34) (13-18, 21,38, 39) . In addition, some growth factors, such as epidermal growth factor and insulin-like growth factor 1, which may act via alterations in signaling pathways involving protein kinases, have been shown to mimic some of the effects of estrogen (14, 40) . cAMP has also been shown to be an important modulator of ER bioactivity, able to synergize with estrogen in enhancing ER transcnptional activity (13, 18) . Our current observations, plus the reports that vitamin D action increases intracellular cGMP (41) , imply a possibly broad involvement of steroid hormone action on cyclic nucleotide and second-messenger systems.
Our data provide evidence for extensive two-way cross talk between estrogen and cAMP signaling pathways: in one way as shown previously (13, 14) , cAMP can enhance the transcription of estrogen-regulated genes containing EREs; in the other way, as shown here, estrogens can act via the cAMP system to regulate cAMP-mediated gene expression. The We are very grateful to Drs. Marc Montminy and Pierre Chambon for providing plasmids, Dr. Richard Goodman for providing CREbinding protein CREB, and Dr. Victor Ramirez for providing antiserum to cAMP. We thank Dr. Alan Wakeling and ICI Pharmaceuticals for providing the antiestrogens. This work was supported in part by National Institutes of Health Grants CA51482 and CA18119 and Predoctoral Traineeship 5T32GM7143.
